Dupixent® (dupilumab) Significantly Reduced COPD Exacerbations in Second Positive Phase 3 Trial, Accelerating FDA Submission and Confirming Potential to Become First Approved Biologic for This Serious Disease

NOTUS trial met its primary endpoint with overwhelming efficacy, showing Dupixent significantly reduced exacerbations by 34% compared to placebo in patients with moderate-to-severe COPD with evidence...

Related Keywords

United States ,Paris ,France General ,France ,Japan ,Naimish Patel ,Eva Schaefer Jansen ,Nathalie Pham ,Sharon Chen ,Felix Lauscher ,Corentine Driancourt ,Evan Berland ,Vesna Tosic ,Arnaud Delepine ,Regeneron Velocimmune ,Georged Yancopoulos ,Sally Bain ,Euronext ,Board Co ,Nasdaq ,Head Of Global Development ,Dupilumab Development Program ,Drug Administration ,Exchange Commission ,Linkedin ,Regeneron Pharmaceuticals Inc ,Regeneron Genetics Center ,Clinical Research Program ,Trial Program ,Board Co Chair ,Chief Scientific Officer ,Breakthrough Therapy ,Global Development ,New England Journal ,Chief Scientific Officer George ,Nasal Polyposis ,Prescribing Information ,Regeneron Genetics ,Forward Looking Statements ,Regeneron Pharmaceuticals ,Product Candidates ,Private Securities Litigation Reform Act ,Statement Regarding Forward Looking ,Elgoutni Tel ,Markets ,